PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August - PDS Biotechnology (NASDAQ:PDSB)
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - PDS B